Device Trial Radar · NCT03784027
The Artificial Pancreas in Very Young Children With T1D
Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
May 1, 2019
Primary completion
Feb 22, 2021
Study completion Oct 3, 2022
Sponsor
- Lead sponsor
- University of CambridgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission; Cambridge University Hospitals NHS Foundation Trust; The Leeds Teaching Hospitals NHS Trust; University of Luxembourg; University of Leipzig; Medical University of Graz; Medical University Innsbruck; Medical University of Vienna; Jaeb Center for Health Research; University of Edinburgh; Stanford University; Glooko
- First posted
- Dec 21, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 1 year, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF. It evaluates the use of the Artificial Pancreas (closed loop system) in very young children with type 1 diabetes (T1D) aged 1-7 years. This outcome study aims to determine whether 24/7 automated closed loop glucose control improves time in range compared to sensor augmented pump therapy. An extension phase will evaluate the effect of long-term home use of the 24/7 automated hybrid closed loop insulin delivery system on glucose control (UK sites only). The study employs an open-label, multi-centre, multi-national, randomized, two-period, crossover design. Participants undergo a 2-4 week run-in period, followed by two 16-week treatment periods (one for each therapy) separated by a 1-4 week washout. The order of treatments is randomized. Up to 80 young children (with a target of 72 randomized subjects) on insulin pump therapy will be recruited from paediatric outpatient diabetes clinics. Before using the study devices, participants and their parents/guardians receive training on the safe use of the study pump, continuous glucose monitoring (CGM) device, and hybrid closed loop system. Nursery or school carers may also be trained if needed. During the closed loop arm, subjects use the system for 16 weeks under free-living conditions at home and in nursery/school without remote monitoring. In the control arm, subjects use sensor augmented pump therapy for 16 weeks under similar conditions, with regular contact and 24/7 telephone support from the study team. The primary endpoint is the time spent in the target glucose range (3.9-10.0 mmol/l) as recorded by CGM. Secondary outcomes include the time spent with glucose levels above and below target and other CGM metrics. Safety assessments include the frequency and severity of hypoglycaemic episodes and diabetic ketoacidosis (DKA). In the extension phase, participants have follow-up contacts every 3 months, with the primary endpoint measured over 18 months from the end of the primary phase and compared to sensor augmented pump therapy during that phase. Secondary outcomes, safety, and utility will be assessed similarly.
Conditions
- Type 1 Diabetes Mellitus
Interventions
CamAPS FXDevice
CamAPS FX closed loop system comprises: * Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) * Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) * An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor * Cloud upload system to monitor CGM/insulin data
Sensor augmented therapyOther
Study insulin pump and study CGM.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time in Target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl)Time frame: 16-week home stay
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Medical University of Graz Department of Pediatrics and Adolescent Medicine
Graz, Austria
Medical University of Innsbruck Department of Pediatrics I
Innsbruck, Austria
Medical University of Vienna Department of Pediatrics
Vienna, Austria
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.